Final phase 3 EORTC 1333/PEACE-3 data show enzalutamide plus radium-223 extends OS and radiographic progression-free survival in mCRPC with bone metastases. Final data from the phase 3 EORTC ...
For patients with mCRPC with bone metastases, the addition of radium-223 to enzalutamide therapy is associated with improved overall survival.
Sexual function data support enzalutamide as monotherapy and combined with leuprolide in patients with high-risk biochemically recurrent prostate cancer. Enzalutamide monotherapy maintains sexual ...
XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the European Union (EU) XTANDI ...
Higher tumor uptake of FG-3180, a CD46 directed PET imaging agent, demonstrated a trend towards higher probability of PSA50 response, highlighting its potential for patient selection Combination ...
Enzalutamide is the first androgen receptor signaling inhibitor approved by the FDA in this setting. The FDA has approved enzalutamide (Xtandi®) for earlier use in prostate cancer in the nonmetastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results